Virus-Like Particle Vaccines for Norovirus – A Promising Immunological Strategy

Introduction: Public Health Challenges of Norovirus and Vaccine Needs

Norovirus (NV) is one of the most prevalent global pathogens causing acute gastroenteritis, with high pathogenicity in children and the elderly. It triggers widespread outbreaks in kindergartens, nursing homes, and other crowded settings, leading to severe symptoms like vomiting and diarrhea and heavy health burdens.

Its high variability and strong transmissibility hinder control. Genetic mutations create new strains that evade pre-existing immunity, and it spreads via person-to-person contact, contaminated food/water, and vomit aerosols. Currently, there are no effective vaccines or specific treatments for norovirus.

Traditional vaccine development faces multiple obstacles: complex viral structure complicates identifying immune-inducing components, high antigenic variability limits cross-strain protection, and the lack of effective animal models delays preclinical efficacy and safety evaluations.

Against this backdrop, virus-like particles (VLPs) have become a key direction for norovirus vaccine development. As a vaccine platform, VLPs have clear structures, strong immunogenicity, and high safety, addressing many shortcomings of traditional platforms.

Basic Principles and Advantages of Virus-Like Particles (VLPs)

Definition and Structure of VLPs

VLPs are non-infectious particles formed by self-assembly of viral structural proteins. They mimic the morphology of natural viruses (e.g., icosahedral structure) but lack viral nucleic acids, so they cannot replicate in host cells or cause infection. Viral capsid proteins, for instance, inherently self-assemble into VLP structures similar to native viruses.

Immunogenic Mechanism of VLPs

VLPs stimulate both innate and adaptive immunity. For innate immunity, they are recognized by pattern recognition receptors (e.g., Toll-like receptors, TLRs) in the host, activating macrophages and dendritic cells. These cells secrete cytokines to recruit immune cells and initiate adaptive immunity.

In adaptive immunity, VLPs induce neutralizing antibodies and T cell responses. Their structural similarity to natural viruses allows B cell recognition; B cells differentiate into plasma cells that produce antibodies to block viral entry into host cells. Antigen-presenting cells (APCs) also process and present VLPs to T cells, activating CD4+ helper T cells (aiding B and CD8+ T cell activation) and CD8+ cytotoxic T cells (killing infected cells).

Advantages of VLPs

• High safety: No viral nucleic acids eliminate infection risk, making VLPs safe for vulnerable groups like children and the elderly.
• Controllable production: VLPs can be produced via bacterial, yeast, or mammalian cell systems, with strict quality control over purity, structure, and immunogenicity.
• Multivalent design: They can display antigens from multiple viral strains, enabling vaccines against multiple pathogens or norovirus serotypes.
• Broad applicability: VLPs have been used in vaccines for HPV, HBV, and influenza, proving versatile for emerging viral pathogens.

Fig.1 Structure and Variable Antigenic Sites of Human Norovirus VP1.^1,2

Structure of Norovirus and Vaccine Development

Structural Characteristics of Norovirus

Norovirus has a relatively simple structure, consisting of several structural proteins, with VP1 being the main antigenic protein. The VP1 protein forms the capsid of the virus, which is responsible for protecting the viral nucleic acid and mediating the attachment of the virus to host cells. The VP1 protein can be divided into two main domains: the shell (S) domain and the protruding (P) domain. The S domain forms the inner shell of the capsid and is involved in the assembly and stability of the virus particle. The P domain is located on the surface of the capsid and contains the major antigenic epitopes that are recognized by the host immune system. These antigenic epitopes are crucial for the induction of neutralizing antibodies, as they are the sites where antibodies bind to the virus and prevent it from infecting host cells. In addition to VP1, norovirus also contains other structural proteins, such as VP2 and VP3, although their functions are not as well-characterized as that of VP1. VP2 is thought to be involved in the assembly and stability of the virus particle, while the role of VP3 remains largely unknown.

Application of VLPs in Norovirus Vaccine Development

VLP vaccines based on the VP1 protein have shown great potential in norovirus vaccine development. By expressing the VP1 protein in appropriate expression systems, such as insect cells or yeast cells, the VP1 protein can self-assemble into VLPs that closely resemble the structure of natural norovirus particles. These VP1-based VLPs can effectively simulate the structure of norovirus, making them capable of inducing both neutralizing antibody responses and cellular immune responses in the host.

In preclinical studies, animals immunized with VP1-based VLP vaccines have been shown to produce high levels of specific neutralizing antibodies. These antibodies can effectively bind to norovirus particles and prevent them from attaching to and entering host cells, thereby providing protection against norovirus infection. Additionally, the VLP vaccines can also activate T cell responses, including the activation of CD4+ helper T cells and CD8+ cytotoxic T cells. The CD4+ helper T cells play a crucial role in the maturation and differentiation of B cells, which are responsible for the production of antibodies. The CD8+ cytotoxic T cells, on the other hand, can directly kill norovirus-infected cells, thereby eliminating the virus from the host.

Multivalent Vaccine Strategy for Norovirus

Norovirus exists in multiple serotypes, with GI.1 and GII.4 being among the most common and clinically important serotypes. The high variability of norovirus serotypes means that a vaccine developed against a single serotype may not provide protection against other serotypes. Therefore, the development of multivalent VLP vaccines has become a key strategy in norovirus vaccine development.

Multivalent VLP vaccines can be constructed by combining VLPs derived from different norovirus serotypes. For example, a bivalent VLP vaccine could include VLPs from the GI.1 and GII.4 serotypes. By immunizing individuals with such a multivalent vaccine, the immune system can be stimulated to produce neutralizing antibodies against both serotypes, thereby providing broader protection against norovirus infection.

The development of multivalent VLP vaccines faces some challenges, such as ensuring the stability and immunogenicity of each VLP component in the vaccine. However, recent studies have shown that multivalent VLP vaccines can be successfully developed and that they can induce strong and specific immune responses against multiple norovirus serotypes. For example, in animal studies, multivalent VLP vaccines have been shown to induce high levels of neutralizing antibodies against each of the included serotypes, and the antibodies have been shown to be effective in preventing infection with the corresponding serotypes.

Development and Challenges of VLP Vaccines

Vaccine Design Strategies

• Structure-guided protein design: Uses VP1 crystal structures to identify antigenic epitopes and modify VP1 (e.g., mutations to expose epitopes) for enhanced immunogenicity, stability, or self-assembly.
• Multivalent vaccines: Beyond norovirus serotypes, they can include antigens from other enteric viruses (e.g., rotavirus) to protect against multiple gastroenteritis causes, requiring compatibility checks for components.
• P particle application: The P domain of VP1 self-assembles into P particles (smaller than full VP1 VLPs) with major epitopes. They are more stable, easy to produce in bacterial systems, and can be modified for multivalent designs, inducing strong neutralizing responses in animals.

Production and Scale-Up of VLPs

VLP production involves protein expression, purification, and self-assembly, each with challenges. Expression systems vary: bacterial systems are cheap but lack post-translational modifications; mammalian cell systems produce native-like proteins but are costly. Purification uses chromatography (ion exchange, size exclusion) to remove impurities, which affects VLP assembly and immunogenicity. Self-assembly depends on pH, temperature, and protein concentration—deviations cause aggregates or incomplete VLPs.

High costs and scale-up difficulties persist. Complex systems and multiple purification steps increase costs, while scaling from lab to industrial levels requires robust manufacturing and quality control.

Clinical Progress and Challenges

Animal models show VLP vaccines induce strong immunity and protection, supporting clinical trials. However, human trials face hurdles: animal models (mice, non-human primates) do not fully mimic human norovirus infection, making efficacy predictions uncertain. Trials must evaluate safety and immunogenicity across ages and immune statuses. Demonstrating clinical efficacy is hard due to norovirus variability and unpredictable outbreaks; human challenge studies have ethical concerns.

Future Outlook and Technological Advances

Novel Vaccine Platforms

• Plant expression systems: Plant cell cultures or whole plants are cost-effective, scalable, and enable oral administration (inducing mucosal immunity critical for enteric viruses). Tobacco-produced norovirus VLPs induce neutralizing antibodies in mice. This field is emerging but promising.
• Nanotechnology and delivery systems: Nanoparticles (e.g., lipid nanoparticles, LNPs) encapsulate VLPs for stability and targeted delivery to dendritic cells. Gold nanoparticles or carbon nanotubes act as adjuvants to boost antibody and T cell responses, improving vaccine efficacy.

Other advances include high-throughput screening (identifying new epitopes), computational biology (predicting protein structure for design), and new adjuvants—all aiding VLP vaccine development.

VLP vaccines are a promising strategy for norovirus control, with clear structures, strong immunogenicity, and high safety. VP1-based VLPs, multivalent designs, and novel platforms (plant systems, nanotechnology) offer potential for broad protection.

However, challenges remain: high production costs, clinical validation needs, and inadequate animal models. With continued research and collaboration between scientists, industry, and regulators, VLP vaccines are expected to play a key role in global norovirus prevention, reducing gastroenteritis burden and improving public health.

Browse our Norovirus Antigen Products

→ Norovirus - Viral Antigens

Need a custom solution? If our off-the-shelf products aren't a perfect fit, we can create one for you. Contact us to design a product that precisely matches your experimental demands.

References

1. Dai, Weiqian, et al. "Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and humoral immune responses in a TLR9-and type I IFN-dependent pathway." Journal of Virology 98.12 (2024): e01699-24. https://doi.org/10.1128/jvi.01699-24
2. Distributed under Open Access license CC BY 4.0, without modification.

Created July 2025

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.